Year: 2023
Type: preprint
Abstract: The goal of precision oncology is to translate the molecular features of cancer into predictive and prognostic tests that can be used to individualize treatment leading to improved outcomes and decreased toxicity.Success for this strategy in breast cancer is exemplified by efficacy of trastuzumab in tumors overexpressing ERBB2 and endocrine therapy for tumors that are estrogen receptor positive.However, other effective treatments, including chemotherapy, immune checkpoint inhibitors, and CDK4/6 inhibitors are not associated with strong predictive biomarkers.Proteomics promises another tier of information that, when added to genomic and transcriptomic features ( proteogenomics), may create new opportunities to improve both treatment precision and therapeutic hypotheses.Here, we review both mass spectrometry-based and antibody-dependent proteomics as complementary approaches.We highlight how these methods have contributed toward a more complete understanding of breast cancer and describe the potential to guide diagnosis and treatment more accurately.G enomic and transcriptomic profiling of >10,000 tumors and normal tissues across 33 cancer types by The Cancer Genome Atlas (TCGA) consortium has revealed enormous genomic complexity and transcriptomic subtypes that may stratify tumors for specific treatments (Blum et al. 2018;Rodon et al. 2019).However, understanding how genomic and transcriptomic aberrations drive clinically relevant can-cer phenotypes to inform precision oncology remains a work in progress.As the functional readout of genomic and transcriptomic aberrations, proteins, with their posttranslational modifications (PTMs) and the accompanied formation of complexes and molecular machines, provide the critical connection between genotype and phenotype.Due to prevalent translational and posttranslational regulation,
Language: English
Subfield: Spectroscopy
Field: Chemistry
Domain: Physical Sciences
Open Access status: bronze
OpenAlex ID: W4367842216